UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

The American journal of cardiology, 2014, Vol.113 (1), p.76-83

2014

Volltextzugriff (PDF)

Management of Cardiovascular Risk: The Importance of Meeting Lipid Targets

The American journal of cardiology, 2012-07, Vol.110 (1), p.3A-14A

2012

Volltextzugriff (PDF)

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Journal of clinical lipidology, 2017-07, Vol.11 (4), p.880-890

2017

Volltextzugriff (PDF)

Recent Clinical Studies of the Effects of Lipid-Modifying Therapies

The American journal of cardiology, 2012-07, Vol.110 (1), p.15A-26A

2012

Volltextzugriff (PDF)

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

The American heart journal, 2009-10, Vol.158 (4), p.513-519.e3

2009

Volltextzugriff (PDF)

Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy

The American journal of cardiology, 2010-05, Vol.105 (9), p.1289-1296

2010

Volltextzugriff (PDF)

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

The American journal of cardiology, 2007-12, Vol.100 (11), p.1659-1664

2007

Volltextzugriff (PDF)

Optimizing statin treatment

Trends in cardiovascular medicine, 2015-04, Vol.25 (3), p.226-227

Gotto, Antonio M., MD, DPhil

2015

Volltextzugriff (PDF)

Integrated Measure for Atherogenic Lipoproteins in the Modern Era

Journal of the American College of Cardiology, 2016, Vol.67 (2), p.202-204

2016

Volltextzugriff (PDF)

Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention

The American journal of cardiology, 2007-03, Vol.99 (5), p.718-725

Gotto, Antonio M., MD, DPhil

2007

Volltextzugriff (PDF)

Prevalence of the Apolipoprotein E Arg145Cys Dyslipidemia At-Risk Polymorphism in African-Derived Populations

The American journal of cardiology, 2014-01, Vol.113 (2), p.302-308

2014

Volltextzugriff (PDF)

Introduction

The American journal of cardiology, 2012, Vol.110 (1), p.1A-2A

Gotto, Antonio M., MD, DPhil

2012

Volltextzugriff (PDF)

Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study)

The American journal of cardiology, 2009-09, Vol.104 (6), p.829-834

2009

Volltextzugriff (PDF)

The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial

Journal of clinical lipidology, 2015-07, Vol.9 (4), p.496-497

Gotto, Antonio M., MD, DPhil

2015

Volltextzugriff (PDF)

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease

Journal of the American College of Cardiology, 2013-12, Vol.62 (22), p.2090-2099

2013

Volltextzugriff (PDF)

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

Journal of the American College of Cardiology, 2014-08, Vol.64 (5), p.485-494

2014

Volltextzugriff (PDF)

The Editor's Roundtable: JUPITER Follow-Up

The American journal of cardiology, 2011-05, Vol.107 (10), p.1549-1557

2011

Volltextzugriff (PDF)

The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids

The American journal of cardiology, 2011-01, Vol.107 (2), p.230-242

2011

Volltextzugriff (PDF)

Cardiologist’s Role in Improving Glucose Control and Global Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus

The American journal of cardiology, 2007-02, Vol.99 (4), p.3-5

Gotto, Antonio M., MD, DPhil

2007

Volltextzugriff (PDF)

The Editor’s Roundtable: The Metabolic Syndrome

The American journal of cardiology, 2007-02, Vol.99 (3), p.382-389

2007

Volltextzugriff (PDF)

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

The Lancet (British edition), 2009-04, Vol.373 (9670), p.1175-1182

2009

Volltextzugriff (PDF)

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

The Lancet (British edition), 2010-07, Vol.376 (9738), p.333-339

2010

Volltextzugriff (PDF)

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

The Lancet (British edition), 2010-02, Vol.375 (9716), p.735-742

2010

Volltextzugriff (PDF)

AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease : 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology

Circulation (New York, N.Y.), 2001-09, Vol.104 (13), p.1577-1579

2001

Volltextzugriff (PDF)

AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology

Journal of the American College of Cardiology, 2001-11, Vol.38 (5), p.1581-1583

2001

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)
Buchkapitel
(1)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Cardiovascular
(23)
Humans
(23)
Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Cardiac & Cardiovascular Systems
(17)
Cardiovascular System & Cardiology
(17)
Cardiovascular Disease
(13)
Cholesterol
(12)
Risk Factors
(12)
Female
(11)
Male
(11)
Middle Aged
(11)
Biological And Medical Sciences
(10)
Cholesterol, Ldl - Blood
(10)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(10)
Medical Sciences
(10)
Aged
(9)
Cardiology
(9)
Statins
(9)
Cardiology. Vascular System
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

Management of Cardiovascular Risk: The Importance of Meeting Lipid Targets

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Recent Clinical Studies of the Effects of Lipid-Modifying Therapies

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

Optimizing statin treatment

Integrated Measure for Atherogenic Lipoproteins in the Modern Era

Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention

Prevalence of the Apolipoprotein E Arg145Cys Dyslipidemia At-Risk Polymorphism in African-Derived Populations

Introduction

Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study)

The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

The Editor's Roundtable: JUPITER Follow-Up

The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids

Cardiologist’s Role in Improving Glucose Control and Global Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus

The Editor’s Roundtable: The Metabolic Syndrome

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease : 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology

AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology

Suchergebnisse filtern